Abstract-In October 2007, the Food and Drug Administration mandated significant revisions to product labeling for the commercially available echocardiographic contrast agents (ECA) Definity and Optison after spontaneous healthcare provider reports of 4 patient deaths and ≈190 severe cardiopulmonary reactions occurring in close temporal relationship to ECA administration. Since then, multiple large ECA safety studies have been published and have included outpatients, hospitalized patients (including the critically ill), patients undergoing stress echocardiography, and patients with pulmonary hypertension. In addition, the Food and Drug Administration has convened 2 Advisory Committee meetings and the product labels for Optison and Definity have been substantially revised with a softening of safety restrictions.
chocardiography is the workhorse of cardiac imaging. It is a portable, cost effective, and noninvasive method for examining cardiac anatomy and function at rest and during stress. Despite significant advances in ultrasound transducer design and signal processing technology, echocardiographic imaging is technically difficult in at least 10% to 15% of patients, chiefly because of patient-related factors including obesity and lung disease. The technically difficult rate is even higher in patients who are undergoing stress echocardiography (because of post-exercise cardiac translation with rapid respiration) and in patients hospitalized in the intensive care unit (because of mechanical ventilation, wound dressings, and chest tubes, among other factors).
In an effort to circumvent these issues, echocardiographic contrast agents (ECAs) were developed. ECAs were first approved in 1990, and there are currently 3 commercially available second-generation ECAs in the United States, including Optison (perflutren protein-type A microspheres; GE Healthcare, Buckinghamshire, UK), Definity (perflutren lipid microsphere; Lantheus Medical Imaging, Billerica, MA), and Lumason (sulfur hexafluoride lipid-type A microspheres; Bracco Diagnostics Inc., Monroe Township, NJ). Characteristics of these ECAs are shown in Table 1. 1-3 They consist of microbubbles with an outer protein or phospholipid shell that encapsulates a fluorocarbon gas. These agents are biologically inert and mimic the rheology of red blood cells in the circulation. 4, 5 Because of their excellent ultrasound scattering characteristics, these agents improve the ability to discriminate between the blood pool and the endocardium and have been approved by the United States Food and Drug Administration (FDA) for use in patients with suboptimal echocardiograms to opacify the left ventricular chamber and to improve the delineation of the left ventricular endocardial border. [6] [7] [8] ECA use salvages technically difficult studies in the intensive care unit, [9] [10] [11] improves accuracy of left ventricular volume and ejection fraction determination, [12] [13] [14] enhances ability to detect left ventricular thrombi, 15 and improves diagnostic accuracy of stress echocardiography. 16, 17 Professional society guidelines, 18 appropriate use criteria, 19 and accreditation bodies, 20 all support judicious use of ECAs, particularly when baseline imaging is compromised.
In October 2007, the FDA mandated significant revisions to product labeling for the commercially available ECAs Definity and Optison (Lumason was not yet approved for use in the United States) after spontaneous healthcare provider reports of 4 patient deaths and ≈190 severe cardiopulmonary reactions occurring in close temporal relationship to ECA administration. 21 This 3-part labeling revision included a new Black Box Warning (BBW; advising of the potential for serious cardiopulmonary reactions) and multiple new disease state contraindications to ECA administration, including acute myocardial infarction or acute coronary syndromes, worsening or decompensated heart failure, serious ventricular arrhythmias, or patients at high risk for arrhythmias based on QT-interval prolongation, as well as respiratory failure, severe emphysema, pulmonary emboli, or other conditions that may cause pulmonary hypertension. In addition, the FDA also required a blanket 30-minute monitoring period after Safety With Echocardiographic Contrast Agents ECA administration in all patients, including ambulatory outpatients.
Since then, multiple large ECA safety studies have been published [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] and have included outpatients, hospitalized patients (including the critically ill), patients undergoing stress echocardiography, and patients with pulmonary hypertension (Table 2 ). In addition, the FDA has convened 2 Advisory Committee meetings, 40, 41 and the product labels for Optison and Definity have been substantially revised with a softening of safety restrictions.
1,2,42 This article will review the safety data for ECAs with topics covered ranging from the mechanisms of ECA-associated adverse events and studies done in special populations.
Adverse Effects of ECAs and Management Strategies
In a meta-analysis (which included 110 500 patients) 43 performed early after the FDA safety alerts in 2007, the incidence of serious allergic and anaphylactoid reactions immediately after ECA administration was estimated at 0.009% and 0.004%, respectively. These very rare but severe allergic reactions are secondary to a recently described variant of the type 1 hypersensitivity reaction known as Complement Activation Related Pseudo Allergy, or CARPA reactions. 44 Unlike the more familiar food and drug allergies we frequently encounter, CARPA reactions are not IgE mediated, no previous exposure is necessary, an allergic reaction tends to be milder or absent on repeated exposure, spontaneous resolution is the rule, and there is a higher reaction rate among the general population, particularly women and patients with pre-existing food and drug allergies (so-called atopic individuals). 24, 44 In addition to ECAs, CARPA reactions may also occur with a variety of other drugs and agents including radiocontrast media, nonsteroidal anti-inflammatory drugs, morphine, liposomal agents, and micellar solvents. To date, these rare allergic reactions are the only patient safety risk associated with ultrasound contrast agents.
Herzog 24 studied adverse events after ECA administration in 16 025 patients (3051 patients received Optison, 12 974 patients received Definity) at Hennepin County Medical Center in Minneapolis, MN. The incidence of severe reactions within 30 minutes of contrast administration was 0.031% (and as the authors noted, similar in frequency to the serious reaction rate reported previously with low-osmolar iodinated radiocontrast media). All of the serious reactions occurred within 20 minutes of ECA administration, and reactions were more common in women (65% of these patients) and individuals with an atopic history (also 65% of patients).
In a separate retrospective, multicenter, study (which included the Hennepin County data), Wei et al 28 reported on the safety of Definity (n=66 164 doses) and Optison (n=12 219 doses)-these included >10 000 doses administered to critically ill patients in the intensive care unit or to patients with presumed ischemic chest pain. Severe reactions likely attributable to the ECA occurred in 8 patients (0.01%), and 4 of these were anaphylactoid reactions. Interestingly, all of the severe reactions occurred in outpatients, indicating that the FDA warning on contrast administration in patients with severe cardiopulmonary conditions likely would not have mitigated risk in these patients.
CARPA reactions may be mild to moderate (sneezing, tingling sensation, urticaria, or pruritis) or severe (wheezing, angioedema, cyanosis, and anaphylactic shock). CARPA reactions seem more common when a large bolus of lipid shelled ECA is injected, and slow continuous infusions of diluted contrast likely afford significant protection against these reactions. It is imperative that sonographers, nurses, and physicians are all trained in the prompt recognition and treatment of these reactions. Although mild reactions may be treated with diphenhydramine or watchful waiting, more severe reactions may require inhaled β-2 agonists for bronchospasm or intramuscular epinephrine for anaphylactic shock. At Saint Luke's Mid America Heart Institute, we provide allergy kits in close proximity to echocardiography machines. Auto injectable epinephrine (available as EpiPen; Mylan Specialty LP, Basking Ridge, NJ) is the most important component of these kits and can be lifesaving. In our experience, it is important to provide these medications separately from the traditional crash-cart to enable rapid point of care administration when necessary.
In addition to the symptoms listed above, back or flank pain is also infrequently experienced with lipid shell ECA administration and has also been reported after administration of others types of liposomal drugs. 45 Liu et al 45 reported that microbubble retention may occur in the renal cortex (in both a murine model and in humans), apparently because of complement-mediated interactions with the glomerular microvascular endothelium-this glomerular retention of lipid shelled microbubbles generates complement-related substances including bradykinin. Microbubble retention is reduced by ≈ 90% in C3-deficient mice, supporting the complement-mediated mechanism.
It is useful to remember there is risk with any form of cardiovascular testing or treatment. Astute clinicians will consider both the risks associated with performance of diagnostic tests (including ECAs) and the risks of misdiagnosis or missed diagnosis when critical diagnostic testing is inappropriately withheld. With a 1:10 000 risk of serious adverse event (anaphylactoid reaction), and a markedly favorable impact on patient outcomes in a variety of patient populations, ECAs have a risk:benefit profile, which is similar to, or better than, comparable techniques. In summary, although anaphylactoid reactions are rare, busy echocardiography laboratories will likely eventually witness a severe allergic reaction. Staff education and provision of potentially lifesaving point of care medications is important from a medical and medical-legal standpoint.
ECA Use in Patients With Serious Cardiac Conditions
The initial FDA action in 2007 specifically contraindicated ECAs in essentially all critically ill patients. Soon thereafter, many safety studies (mostly retrospective and investigator initiated) were published and led to a better understanding of ECA safety in this patient population.
Kusnetzky et al 25 published data on 18 671 consecutive hospitalized patients who underwent echocardiography either with (n=6196) or without an ECA (n=12 475 patients). The mortality rate at 24 hours was similar between patients undergoing unenhanced echocardiography (0.37%) and patients who received an ECA (Definity in all patients; 0.42%; P=0.60). Patients who received an ECA were demonstrably sicker at baseline with a higher prevalence of chronic obstructive pulmonary disease, lower left ventricular ejection fraction, and longer length of stay in the intensive care unit.
Subsequently, in a much larger study of similar design, Main et al 26 reported on 4 300 966 inpatients who underwent echocardiography (58 254 of whom underwent echocardiography with the ECA Definity) and who were included in the Premier Perspective Database (the largest United States hospital-based, service-level, comparative database). Mortality at 24 hours was similar between the noncontrast and ECA groups (1.08% versus 1.06%, respectively; P=0.613). Multivariate logistic regression analysis revealed that patients undergoing echocardiography with an ECA were 24% less likely to die within 24 hours (odds ratio, 0.76; 95% confidence interval, 0.70-0.82). In addition, all patients were assessed for the More recently, Main et al 38 published a propensitymatched outcomes study in critically ill patients undergoing echocardiography either with or without an ultrasound contrast agent. In this study, designed collaboratively by Lantheus Medical Imaging (manufacturer of Definity) and the FDA, the Premier Perspective Database was again utilized to identify 1 006 381 critically ill patients who underwent echocardiography. A propensity scoring algorithm was used to assemble matched cohorts of 16 217 patients who underwent echocardiography with or without Definity. At 48 hours, mortality was lower in the ECA group (1.70% versus 2.5%; odds ratio, 0.66; 95% confidence interval, 0.54-0.80), a difference that persisted throughout the hospital stay (14.85% versus 15.66%; odds ratio, 0.89; confidence interval, 0.84-0.96).
Kurt et al 46 studied 632 patients with technically difficult baseline echocardiograms who underwent additional contrast-enhanced echocardiography with Definity. Clinicians caring for these patients were presented first with findings from the unenhanced echocardiogram, and subsequently with the contrast-enhanced data, and asked to report whether the contrast-enhanced examination impacted clinical management. Overall, ECA use resulted in an important management change in 35.5% of patients (avoidance of a downstream procedure, a change in medication, or both). The impact was greatest in the sickest patients-of 102 patients in the surgical intensive care unit, 62.9% experienced a significant management change related to incremental ECA-enhanced echocardiography-derived data. In addition to the study by Kurt et al, 46 emerging evidence indicates that ECAs are safe and provide potentially lifesaving diagnostic data in even the highest acuity patients-those with left ventricular assist devices 47, 48 or receiving circulatory support via extracorporeal membrane oxygenation 49 (although special care must be taken to avoid extracorporeal membrane oxygenation circuit shut down because of bubble sensing safety systems). 50 In summary, despite initial FDA contraindications to the contrary, there is substantial evidence that ECAs are not only safe in critically ill patients but also that important diagnostic data can potentially be derived from these studies. The current product labeling for ECAs in the United States indicates that the risk for serious cardiopulmonary reactions may be increased among patients with unstable cardiopulmonary conditions (acute myocardial infarction, acute coronary syndromes, worsening or unstable heart failure, or serious ventricular arrhythmias). This warning does not seem to be evidence based and may harm patients given the potential to impede judicious ECA administration in patients most likely to derive benefit.
21,51,52

ECA Use in Patients With Cardiac Shunts
Administration of ECAs in patients with known right to left, bidirectional, or transient right to left intracardiac shunts has been contraindicated by the FDA since each ECA was approved based on theoretical concern for central nervous system microvascular occlusion. This contraindication seems largely based on an animal study 53 aimed at determining the rheology of Definity microspheres after intra-arterial administration (essentially mimicking what could occur after intravenous injection in the presence of an intracardiac shunt). After the intra-arterial injection, a small proportion of Definity microspheres >5 μm in diameter were entrapped within small arterioles and capillaries. However, microvascular occlusion was rare (retention fraction of 1.2%), transient (10 minutes) and was not associated with hemodynamic or local vascular consequences.
In the case of intravenous injection in patients without intracardiac or intrapulmonary shunting, the small quantity of microspheres larger than a red blood cell (<5% for Optison, Definity, and Lumason) are filtered by the pulmonary capillary system without compromising pulmonary hemodynamics.
1-3, 54 In the case of a significant shunt, potential exists for these larger microspheres to escape the pulmonary first pass filter, and proceed unimpeded into the systemic circulation.
In 2013, a position paper was published, 55 arguing that existing empirical and clinical evidence strongly supports the safe use of ultrasound contrast agents in patients with intracardiac shunts, particularly in patients with patent foramen ovale (PFO), based on several lines of evidence.
First, there have been no neurological safety signals in large registry studies that have enrolled all-comers, 26 ,28 despite the fact that based on population statistics, ≈25% of these patients likely had undiagnosed PFOs. At Saint Luke's Mid America Heart Institute, we do not screen patients for shunts before ECA administration (with color Doppler or intravenous agitated saline studies) or have we withheld ECAs when clinically indicated in patients with known PFOs. In addition, to our knowledge, there are no case reports documenting acute neurological sequelae after ECA administration although these events have been rarely reported after intravenous agitated saline studies. [56] [57] [58] Second, Kalra et al 59 recently reported on 39 020 patients who underwent contrast echocardiography either with (n=418) or without (n=38 602) a known intracardiac shunt. No primary adverse events or transient ischemic attacks occurred in the patients with known intracardiac shunts, whereas 1 primary adverse event and 1 transient ischemic attack occurred in the patients without a known shunt.
Third, the FDA contraindication of ECAs in patients with shunts contradicts the FDA's own guidance on macroaggregated albumin, which is used in ventilation-perfusion lung scans. 55 Macroaggregated albumin has a particle size of 10 to 150 μm (with 90% in the 10-to 70-μm range). Despite the theoretical potential for occlusion of arterioles if macroaggregated albumin bypasses first-pass filtration in the lungs, macroaggregated albumin carries only a precaution against use in patients with shunts. In comparison, the FDA issued a contraindication for ECA administration in patients with shunts despite a much smaller microsphere size (Optison mean diameter, 3-4.5 μm [95% <10 μm]; Definity mean diameter, 1.1-3.3 μm [98% <10 μm]) with theoretical occlusion possible only at the capillary level. Safety With Echocardiographic Contrast Agents Finally, intravenous agitated saline studies are routinely performed to exclude PFO in young patients with cryptogenic stroke. 60 These studies utilize large volume (≈10 mL) bolus injections of very large and unstable air-filled microbubbles, typically with concomitant provocative maneuvers such as Valsalva or cough aimed at transiently increasing right atrial pressure and forcing transatrial microbubble passage. Despite the very large volumes of air-filled microbubbles delivered to the systemic circulation, transient neurological symptoms are rare and intravenous agitated saline studies are unregulated by the FDA. [56] [57] [58] In October 2016, the FDA rescinded the shunt contraindication for Optison, 61 (and more recently rescinded the shunt contraindication for Lumason and Definity) but added the following statement to the Warnings and Precautions portion of the product label-"when administering Optison to patients with a cardiac shunt, microspheres can bypass filtering of the lungs and enter the arterial circulation. Assess patients with shunts for embolic phenomena after Optison administration."
In addition, a recent American Society of Echocardiography Guidelines document recommended routine use of ECAs in patients with PFOs when clinically indicated and noted that ECAs have been used safely in patients with corrected or uncorrected congenital heart disease.
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ECA Safety in Pulmonary Hypertension
The initial FDA disease state contraindication list in 2007 included patients with respiratory failure, severe emphysema, pulmonary emboli, or other conditions that may cause pulmonary hypertension. The FDA's theoretical concern was that in patients with pre-existing pulmonary hypertension, occlusion of a portion of the pulmonary microvasculature with microbubbles that exceed 10 μm might lead to hemodynamic compromise (there are ≈5×10 5 microbubbles with a mean diameter >10 μm in each vial of Definity, for example, and Wei et al 63 have estimated that only 1 in 900 capillaries in the lungs could potentially be occluded in an ≈70-kg patient receiving the FDA-approved dose of 10 μL/kg of Definity).
Abdelmoneim et al 32 retrospectively analyzed shortterm (≤72 hours and ≤30 days) and long-term (4.3 years) outcomes (mortality, myocardial infarction, and ventricular arrhythmias) in 16 434 patients (n=10 270 patients with ECA, n=6164 patients without contrast) who underwent stress echocardiography. These patients were categorized according to Doppler-derived right ventricular systolic pressure as ≥35, ≥50, and ≥60 mm Hg (or by tricuspid regurgitation continuous wave Doppler velocity values ≥2.7 or ≥3.5 m/s). Although there were more patients in the contrast cohort with pulmonary hypertension (estimated right ventricular systolic pressure ≥50 mm Hg), there was no significant association between ECA use and increased risk of death or myocardial infarction.
Wever-Pinzon et al 36 evaluated 1513 consecutive hospitalized patients who underwent echocardiography with an ECA (Definity) for short-term (within 24 hours) adverse events. The incidence of adverse events was similar regardless of whether patients had mild (mean pulmonary artery systolic pressure [PASP], 41±4 mm Hg), moderate (mean PASP, 55±5 mm Hg), or severe (mean PASP, 78±9 mm Hg). No adverse reactions were considered directly attributable to the ECA on the basis of temporal and clinical considerations.
Two studies designed in collaboration with the FDA aimed to prospectively determine the safety of ECAs in patients with pulmonary hypertension. Wei et al 63 performed an invasive pulmonary hemodynamic study in 32 patients (16 patients with baseline PASP ≥35 mm Hg and 16 patients with no pulmonary hypertension at baseline). Each patient received a clinically relevant dose of Definity (10 μL/kg) with multiple sequential measurements of right atrial pressure, pulmonary artery pressure, cardiac output, and pulmonary capillary wedge pressure both at baseline and after Definity administration. There were no changes in pulmonary or systemic hemodynamics in any patient. Of note, the mean pulmonary artery systolic pressure in patients with baseline pulmonary hypertension was 50.9±10.3 mm Hg.
In a second study, Main et al 64 evaluated pulmonary hemodynamics in 30 patients who underwent right heart cardiac catheterization (11 patients with normal PASP at baseline and 19 patients with elevated PASP at baseline) after intravenous administration of either 0.5-mL Optison or 0.5 mL of 5% dextrose (single-blind, crossover, placebo-controlled study design). There were no significant changes from baseline after administration of the control solution or Optison in either the baseline normal or baseline elevated, PASP strata.
In addition, 2 previous clinical studies evaluated the safety of ECAs in patients with pulmonary hypertension. Soman et al 65 evaluated the safety of Sonovue (marketed in the United States as Lumason) in 13 patients with severe left ventricular systolic dysfunction (11 of whom had concomitant pulmonary hypertension). After sequential administration of 2 and 4 mL of Sonovue, there were no changes in pulmonary hemodynamics. In addition, Erb and Shanewise 66 evaluated the hemodynamic effects of Optison in 57 patients undergoing cardiac surgery. They found no significant changes in blood pressure, central venous pressure, or pulmonary artery pressure at 5 and 10 minutes after intravenous injection of 0.3 mL of Optison.
In summary, ECAs seem safe in patients with pulmonary hypertension. We administer ECAs when clinically indicated, regardless of pulmonary artery systolic pressure or presence of lung disease, including mechanically ventilated patients. The product labeling for commercially available ECAs continues to list respiratory failure, severe emphysema, pulmonary emboli, or other conditions that may cause pulmonary hypertension as a warning. Based on the available data (including 2 prospective studies designed in collaboration with FDA), this warning may not be evidence based-and likely discourages use in patients likely to benefit from ECA enhanced echocardiography.
ECA Safety in Pediatrics and Pregnancy
To our knowledge, only 2 studies have specifically addressed the issue of ECA safety in the pediatric population. McMahon and colleagues 67 evaluated the safety of Optison in 20 patients ranging in age from 9 to 18 years who received this ECA because of markedly limited transthoracic echocardiography windows at baseline. No patients experienced adverse hemodynamic effects. Kutty et al 68 reported on 113 children Safety With Echocardiographic Contrast Agents and adolescents (mean age, 17.8±3 years; age range, 5-21 years) who received an ECA. There were no serious adverse events and no allergic reactions. In addition, ultrasound contrast agent safety when administered for radiology indications in children has been firmly established, and the recent FDA radiology approval of Lumason includes approval for use in children. 69 There are no data about safety of ECAs in pregnancy. Given lack of any data in this patient subset, prescribing information recommends ECA use in pregnancy only if clearly needed.
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Potential Effect of Pseudocomplication in Assessing ECA Safety
Although adverse events occurring immediately after a medical test or procedure are typically attributed to the test/procedure, this attribution is not always correct. The Latin phrase post hoc, ergo propter hoc (after this, therefore on account of it) 70 describes the potential error in over reliance on temporal relationship in determining attribution. Pseudocomplications (complications that actually occur because of progression of the underlying disease state, and not concurrent diagnostic testing or therapeutic intervention) were first described by Hildner et al 71 in their classic 1973 publication. Hildner et al 71 prospectively catalogued the complications associated with 1036 diagnostic cardiac catheterizations for at their institution-they termed complications that occurred in the 48 hours before to 24 hours after cardiac catheterizations that were scheduled (but not actually performed) pseudocomplications. The pseudocomplication rate (2.6% overall and 1.2% sudden death) was remarkably similar to the true complication rate (2.6% overall and 0.6% deaths), with similar complication types noted in both groups.
The initial 4 patient deaths that occurred in close temporal proximity to ECA administration noted by the FDA in October 2007 (at the time of the initial BBW) certainly raise the possibility of pseudocomplication. 21 Patient 1 had been diagnosed with an ischemic cardiomyopathy and died 1 minute after initiating an exercise treadmill test (and 30 minutes after receiving an ECA). Patient 2 was an elderly man admitted to the intensive care unit with a recent myocardial infarction and severe left ventricular systolic dysfunction. He received a sedative for anxiety and then underwent contrast-enhanced echocardiography. He had a cardiac arrest shortly after completion of the study. Patient 3 was a 70-year-old man with previous coronary artery bypass grafting, heart failure, and deep vein thrombosis. He became cyanotic and hypotensive ≈5 minutes after completion of a contrast-enhanced echocardiogram. A massive pulmonary embolism was reported as the probable cause of death. Patient 4 was a 34-year-old morbidly obese woman (>350 lbs) critically ill with trilobar pneumonia and postpartum cardiomyopathy-she required vasopressors and mechanical ventilation. She had a cardiac arrest immediately after ECA administration. A subsequent postmortem examination revealed multiple pulmonary emboli and a large right ventricular thrombus.
Data from several large studies that compared acute mortality in patients undergoing echocardiography either with or without an ECA, confirm that pseudocomplication may be a likely explanation for observed/reported events. Short-term mortality rates (1-2 days) in hospitalized patients undergoing echocardiography without an ECA ranged from 0.4% to 2.5%, attesting to the critically ill nature of these patients. 25, 26, 38 In this patient population, misattribution of causality in patients experiencing adverse reactions after ECA administration likely occurs frequently, a reminder that the true complication rate of any procedure or diagnostic test cannot be accurately ascertained without a firm understanding of the background ambient incidence of untoward clinical outcome in the population under study.
Current Status of the BBW
After the initial BBW in October 2007, multiple investigatorinitiated safety studies were rapidly published-these studies included stable outpatients, hospitalized patients, and patients undergoing stress echocardiography. [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] With this largely exculpatory safety data in hand, and with a better realization of the benefit:risk profile of ECAs, the FDA announced in May 2008 that the disease state contraindications would be deleted 40 and that these clinical disease states would subsequently only appear in product labeling as a warning.
On June 24, 2008 , the FDA convened a meeting of the Cardiovascular and Renal Drugs Advisory Committee to review the preclinical safety evaluation of ECAs and potential class effects related to the risk profile of ECAs. 40 The panel also reviewed a proposed 3-part post-marketing safety study plan developed by the FDA in conjunction with Lantheus Medical Imaging (Definity) and GE Healthcare (Optison). These included (1) a prospective registry of ≈1000 patients to determine the risk of death or serious adverse event in patients receiving an ECA in routine clinical practice, (2) a prospective invasive hemodynamic study in patients with either elevated or normal baseline pulmonary artery systolic pressure to determine the hemodynamic effect of a clinically relevant dose of ECA on pulmonary artery systolic pressure and pulmonary vascular resistance, and (3) a large propensitymatched outcomes study in critically ill patients undergoing echocardiography either with or without an ECA, similar in design to previously performed retrospective studies.
A subsequent combined meeting of the FDA Cardiovascular and Renal Drugs Advisory Committee and the Drug Safety Advisory Panel was convened on May 2, 2011, to review the results of the 3-part risk-mitigation studies agreed to by the FDA and the US ECA manufacturers in 2008 41 and to discuss whether further label changes should be considered for the ECA class. All 6 safety studies (3 each per manufacturer) showed reassuring results. 33, 35, 38, 39, 63, 64 There were no deaths or serious adverse events in either clinical care registry, there was no significant change in pulmonary artery systolic pressure or pulmonary vascular resistance after clinically relevant dosing of either ECA and the large propensity-matched database studies including critically ill patients revealed no increase in mortality risk for patients undergoing echocardiography with an ECA, compared with those undergoing unenhanced echocardiography (Table 3) .
Based on these studies and other considerations, the FDA announced in October 2011 a further revision for ECA product labeling. The extremely rare (≈1:10 000) risk of idiosyncratic anaphylactoid reaction associated with ECA administration may not support a continued BBW given these criteria developed by FDA. Indeed, virtually all drugs and contrast agents might carry a BBW if held to this same standard.
Conclusions
It has now been 9 years since the FDA imposed a BBW and multiple disease state contraindications for ECAs. Despite a large number of studies that have established a strong safety profile for these agents, and FDA acknowledgment through product label revision that ECAs have an acceptable risk:benefit relationship, safety data of ECAs may be underappreciated, which likely has led to underutilization in patient populations likely to derive benefit. ECAs are safe in patients with serious cardiopulmonary conditions and intracardiac shunts, and the safety profile of these agents compares favorably with other commonly performed cardiac tests. The risk of severe allergic reactions with ECAs is low (≈1:10 000 doses); however, echocardiography laboratory personnel ought to be prepared to recognize and treat these reactions, including emergency administration of intramuscular epinephrine in the most serious cases. Despite language included in the product label (the risk for these reactions may be increased among patients with unstable cardiopulmonary conditions), there are essentially no data to support this contention. It is clear, however, that patients with limited cardiopulmonary reserve (such as a patient with acute myocardial infarction or acute on chronic systolic heart failure) will be poorly equipped to tolerate a severe allergic reaction. Given the high clinical acuity of hospitalized patients undergoing echocardiography in general, and contrast echocardiography in particular, it is likely that many cases of clinical decompensation occurring in close temporal relationship to ECA administration have been incorrectly attributed to the ECA. Finally, although the BBW has not been rescinded, the FDAs own internal guidance suggests that application of a BBW is not supported for drugs or contrast agents that are associated with rare, idiosyncratic, adverse events. 
